{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T13:00:22Z","timestamp":1792069222269,"version":"4.4.0"},"reference-count":32,"publisher":"Japanese Society of Hypertension","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2005]]},"DOI":"10.1291\/hypres.28.555","type":"journal-article","created":{"date-parts":[[2006,4,6]],"date-time":"2006-04-06T14:03:08Z","timestamp":1144332188000},"page":"555-563","source":"Crossref","is-referenced-by-count":42,"title":["Telmisartan\/Hydrochlorothiazide in Comparison with Losartan\/Hydrochlorothiazide in Managing Patients with Mild-to-Moderate Hypertension"],"prefix":"10.1291","volume":"28","author":[{"given":"Joel M.","family":"NEUTEL","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas W.","family":"LITTLEJOHN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven G.","family":"CHRYSANT","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish","family":"SINGH","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"119","reference":[{"key":"1","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-199917020-00001"},{"key":"2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000107251.49515.c2"},{"key":"3","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(90)90944-Z"},{"key":"4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)11911-8"},{"key":"5","doi-asserted-by":"publisher","DOI":"10.1097\/00126097-200104000-00001"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Muller JE, Ludmer PL, Willich SN, <i>et al<\/i>: Circadian variation in the frequency of sudden cardiac death. <i>Circulation<\/i> 1987; <b>75<\/b>: 131-138.","DOI":"10.1161\/01.CIR.75.1.131"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Muller JE, Stone PH, Turi ZG, <i>et al<\/i>: Circadian variation in the frequency of onset of acute myocardial infarction. <i>N Engl J Med<\/i> 1985; <b>313<\/b>: 1315-1322.","DOI":"10.1056\/NEJM198511213132103"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Mulcahy D, Keegan J, Cunningham D, <i>et al<\/i>: Circadian variation of total ischaemic burden and its alteration with anti-anginal agents. <i>Lancet<\/i> 1988; <b>2<\/b>: 755-759.","DOI":"10.1016\/S0140-6736(88)92414-2"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Mancia G, Parati G: Ambulatory blood pressure monitoring and organ damage. <i>Hypertension<\/i> 2000; <b>36<\/b>: 894-900.","DOI":"10.1161\/01.HYP.36.5.894"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Quyyumi AA: Circadian rhythms in cardiovascular disease. <i>Am Heart J<\/i> 1990; <b>120<\/b>: 726-733.","DOI":"10.1016\/0002-8703(90)90044-X"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Timmermans PB: Angiotensin II receptor antagonists: an emerging new class of cardiovascular therapeutics. <i>Hypertens Res<\/i> 1999; <b>22<\/b>: 147-153.","DOI":"10.1291\/hypres.22.147"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Siragy HM: Angiotensin receptor blockers: how important is selectivity? <i>Am J Hypertens<\/i> 2002; <b>15<\/b>: 1006-1014.","DOI":"10.1016\/S0895-7061(02)02280-X"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Stangier J, Su C-APF, Roth W: Pharmacokinetics of orally and intravenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patients. <i>J Int Med Res<\/i> 2000; <b>28<\/b>: 149-167.","DOI":"10.1177\/147323000002800401"},{"key":"14","doi-asserted-by":"publisher","DOI":"10.1016\/0009-9236(95)90020-9"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Christen Y, Waeber B, Nussberger J, <i>et al<\/i>: Oral administration of DuP 753a specific angiotensin II receptor antagonist, to normal male volunteers. Inhibition of pressor response to exogenous angiotensin I and II. <i>Circulation<\/i> 1991; <b>83<\/b>: 1333-1342.","DOI":"10.1161\/01.CIR.83.4.1333"},{"key":"16","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-200111000-00004"},{"issue":"5","key":"17","doi-asserted-by":"crossref","first-page":"820","DOI":"10.2165\/00003495-199651050-00008","volume":"51","year":"1996","ISSN":"https:\/\/id.crossref.org\/issn\/0012-6667","issn-type":"print"},{"key":"18","doi-asserted-by":"publisher","DOI":"10.1291\/hypres.27.545"},{"key":"19","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-200306000-00001"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Waeber B: Combination therapy with ACE inhibitors\/angiotensin II receptor antagonists and diuretics in hypertension. <i>Expert Rev Cardiovasc Ther<\/i> 2003; <b>1<\/b>: 43-50.","DOI":"10.1586\/14779072.1.1.43"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Smith DH, Neutel JM, Lacourci&egrave;re Y, Kempthorne-Rawson J: Prospective, randomized, open-label, blinded-endpoint (PROBE) designed trials yield the same results as double-blind, placebo-controlled trials with respect to ABPM measurements. <i>J Hypertens<\/i> 2003; <b>21<\/b>: 1237-1239.","DOI":"10.1097\/00004872-200307000-00016"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. American Society of Hypertension: Recommendations for routine blood pressure measurement by indirect cuff sphygmomanometry. <i>Am J Hypertens<\/i> 1992; <b>5<\/b>: 207-209.","DOI":"10.1093\/ajh\/5.4.207"},{"issue":"10","key":"23","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.2165\/00003495-200161100-00009","volume":"61","author":"SHARPE M","year":"2001","ISSN":"https:\/\/id.crossref.org\/issn\/0012-6667","issn-type":"print"},{"key":"24","doi-asserted-by":"publisher","DOI":"10.1291\/hypres.27.457"},{"key":"25","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jhh.1000925"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Lacourci&egrave;re Y, Gil-Extremera B, Mueller O, <i>et al<\/i>: Efficacy and tolerability of fixed-dose combinations of telmisartan plus HCTZ compared with losartan plus HCTZ in patients with essential hypertension. <i>Int J Clin Pract<\/i> 2003; <b>57<\/b>: 273-279.","DOI":"10.1111\/j.1742-1241.2003.tb10484.x"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Elliott HL: Angiotensin II antagonists: efficacy, duration of action, comparison with other drugs. <i>J Hum Hypertens<\/i> 1998; <b>12<\/b>: 271-274.","DOI":"10.1038\/sj.jhh.1000637"},{"issue":"6","key":"28","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1161\/01.HYP.25.6.1345","volume":"25","year":"1995","ISSN":"https:\/\/id.crossref.org\/issn\/0194-911X","issn-type":"print"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Messerli FH: ... and losartan was no better than placebo. <i>J Hum Hypertens<\/i> 1999; <b>13<\/b>: 649-650.","DOI":"10.1038\/sj.jhh.1000926"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Burnier M, Maillard M: The comparative pharmacology of angiotensin II receptor antagonists. <i>Blood Press<\/i> 2001; <b>10 <\/b>(Suppl 1): 6-11.","DOI":"10.1080\/080370501750066444"},{"key":"31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022273"},{"key":"32","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000056521.67546.AA"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","deposited":{"date-parts":[[2023,5,6]],"date-time":"2023-05-06T23:16:18Z","timestamp":1683414978000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.nature.com\/doifinder\/10.1291\/hypres.28.555"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005]]},"references-count":32,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2005]]}},"URL":"https:\/\/doi.org\/10.1291\/hypres.28.555","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005]]}}}